(i) our statements regarding the therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject ...
NEW YORK, Jan ...NKTR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980 ... [Click here for information about joining the class action] ... Founded by the late Abraham L ... 7980 ... 21% ... .
